DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for telangiectatic osteogenic sarcoma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleTelangiectatic osteogenic sarcoma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for telangiectatic osteogenic sarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cyclin dependent kinase 12 (CDK12) — CDK12 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4NST · 2.2 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Of 1480 osteogenic sarcoma cases seen at Memorial and James Ewing Hospitals between 1925 and 1971, 29 were diagnosed as telangiectatic osteogenic sarcoma. Nineteen males and 10 females, average age 20 years, presented most often with tumours in the distal femur, proximal humerus, and proximal tibia. Five of 28 patients survived, an 18% survival rate comparable to that for osteogenic sarcoma as a group at that hospital. The authors concluded that while telangiectatic osteogenic sarcoma is a distinct histologic entity, distinguishing it carried no prognostic implication.
Between 1973 and 1980, 25 patients with pure telangiectatic osteogenic sarcoma of an extremity were treated with adjuvant chemotherapy and surgery. Ten patients received high-dose methotrexate with citrovorum factor rescue, Adriamycin, and cyclophosphamide (protocol T-4); five of those ten remained disease-free for seven to ten years. Nine patients received high-dose methotrexate with citrovorum factor rescue, Adriamycin, and bleomycin-cyclophosphamide-dactinomycin (protocol T-7); six of those nine were disease-free survivors at a median of 63 months. Six patients received protocol T-10 (high-dose methotrexate with citrovorum factor rescue, Adriamycin, bleomycin-cyclophosphamide-dactinomycin, with cisplatin substituted for non-responders); all six were disease-free survivors at a median of 49 months. Two drug-related deaths from high-dose methotrexate occurred before 1977. Overall, 17 of 25 patients (68%) remained free of disease at a mean follow-up exceeding five and a half years. The authors concluded that telangiectatic osteogenic sarcoma is responsive to chemotherapy and potentially curable.
A 2013 literature review noted that telangiectatic osteosarcoma is a rare variant whose occurrence, presentation, and prognosis remain poorly understood. It stated that chemotherapy with surgery, previously challenged, has now been proved beneficial. A separate 1975 study of 130 osteogenic sarcoma patients found a five-year survival rate of 25.5% (26 of 102 who had radical surgery) and reported a therapeutic regimen of regional perfusion, amputation, bronchial artery infusion, and systemic anticancer agents. Another 1975 paper argued that effective chemotherapeutic agents given shortly after definitive primary treatment had altered the natural history of osteogenic sarcoma, with pulmonary metastases failing to develop in the overwhelming majority of patients receiving chemotherapy.
What is still missing is prospective data specific to telangiectatic osteogenic sarcoma, given its rarity; consistent diagnostic criteria to distinguish pure from mixed subtypes; and a trial design that can stratify patients by histologic variant within the larger osteosarcoma population to confirm whether the 68% disease-free survival reported in the 1986 series is reproducible outside a single institution.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Cancer · 1974 · 50 citations · open access
Telangiectatic osteogenic sarcoma:A review of twenty-eight cases
AbstractTelangiectatic osteogenic sarcoma has been recognized as a distinct form of osteogenic sarcoma since the early part of this century. Dr. James Ewing's encouragement to study the lesion thoroughly has not resulted in what we consider an adequate published evaluation of its clinical behavior. Approximately 1480 cases of osteogenic sarcoma have been seen at the Memorial and James Ewing Hospitals between 1925 and the end of 1971. Twenty-nine of these were diagnosed as telangiectatic osteogenic sarcoma. The 19 males and 10 females ranged in age from 5 to 62 years, with an average age of 20 years. The most common locations of the tumors were in the distal femur, proximal humerus, and proximal tibia. Five of 28 patients survived their diseases. This 18% survival rate is comparable to the results of therapy at Memorial Hospital for osteogenic sarcoma as a group. These data indicate to us that whereas telangiectatic osteogenic sarcoma is a distinct histologic entity, distinguishing this type is academic since there is no prognostic implication.
Clinical Orthopaedics and Related Research · 1986 · 43 citations
Telangiectatic Osteogenic Sarcoma
AbstractSince the inception of adjuvant chemotherapy for osteogenic sarcoma (OS), 25 patients were treated for telangiectatic osteogenic sarcoma (TOS) from 1973 through 1980. This represented 12% of all patients with primary OS of an extremity seen during this time period. Tumors that demonstrated only focal areas of TOS with areas of other subtypes were designated not as TOS but as "mixed" subtypes of OS. In the 25 patients with pure TOS, surgery included 18 amputations and seven resections for the primary tumor. Ten patients were treated on the first chemotherapy protocol (T-4) including high-dose methotrexate (HDMTX) with citrovorum factor rescue (CFR), Adriamycin (ADR), and cyclophosphamide (CYC). Of those 10 patients, five have been free of disease for seven to ten years from the time of diagnosis. Nine patients were treated on the second protocol (T-7) including HDMTX with CFR, ADR, and the combination bleomycin, cyclophosphamide, and dactinomycin (BCD). Six of those nine patients are disease-free survivors 63 to 88 months (median, 63 months) from diagnosis. Six were treated on the third chemotherapy protocol (T-10) including HDMTX with CFR, ADR, BCD, and the substitution of cisplatinum for those not having a complete response to preoperative chemotherapy with HDMTX. All six of the latter are disease-free survivors 42 to 56 months (median, 49 months) from the start of treatment. Toxicity included two HDMTX-related drug deaths in patients started on treatment prior to 1977. Of the entire group, 17/25 (68%) have remained free of disease at a mean follow-up time of over five and one-half years. This study demonstrates that TOS is responsive to chemotherapy and is potentially curable. Some prior reports of the uniformly poor prognosis of this variant of OS should not discourage attempts of curative therapy by chemotherapy and surgery.
OncoTargets and Therapy · 2013 · 42 citations · open access
 Telangiectatic osteosarcoma: a review of literature
AbstractTelangiectatic osteosarcoma is a rare variant of osteosarcoma and hence its occurrence, presentation, and prognosis are poorly understood. With advancements in technology and available treatment options, the scenario of its diagnosis, management, and outcome has changed. Chemotherapy with surgery was challenged previously, but has now been proved to be beneficial. We reviewed the available literature and compared results to define the characteristics of the disease, its presentation, radiographic and pathologic features, optimal treatment, and prognosis.
Journal of Bone and Joint Surgery · 1975 · 31 citations
Osteogenic sarcoma. A study of one hundred and thirty cases
AbstractOne hundred and thirty patients with osteogenic sarcoma were studied clinically, roentgenographically, and pathologically. Prognosis by each of ten factors was analyzed with the Wilcoxon test. The test yielded p smaller than 0.05 in a comparison between the survival curves of patients fifteen years old or younger and that of patients over fifteen, but other comparisons did not yield p smaller than 0.05. The actual five-year survival rate was 25.5 per cent (twenty-six of 102 patients who had radical surgery). Our therapeutic regimen for osteogenic sarcoma at the present time consists of regional perfusion, amputation, bronchial artery infusion, and systemic administration of anticancer agents.
Clinical Orthopaedics and Related Research · 1975 · 13 citations
The Potential for an Improved Prognosis with Chemotherapy in Osteogenic Sarcoma
AbstractEffective chemotherapeutic agents administered shortly after definitive primary treatment to patients with osteogenic sarcoma have altered the natural history of the disease. In contrast to past experience, pulmonary metastases fail to develop in the overwhelming majority of patients receiving treatment with chemotherapy. Patients with established pulmonary metastases have also been salvaged. The therapeutic strategy advocated for different categories of patients is outlined. Although chemotherapy involves additional hospitalization and inconvenience, this additional mode of treatment appears to be the only mechanism by which a substantial improvement in survival of osteogenic sarcoma can presently be achieved.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
